atomoxetine

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Attention-Deficit/Hyperactivity Disorder (ADHD)

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia

Trial Timeline

Nov 1, 2005 → —

NCT ID

NCT00252278

About atomoxetine

atomoxetine is a approved stage product being developed by Eli Lilly for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is unknown. This product is registered under clinical trial identifier NCT00252278. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia.

What happened to similar drugs?

7 of 10 similar drugs in Attention-Deficit/Hyperactivity Disorder (ADHD) were approved

Approved (7) Terminated (0) Active (3)

✅AtomoxetineEli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

✅100mg SPN-812 + PlaceboSupernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01177943	Phase 1	Completed	Aug 1, 2010	Oct 1, 2010	Attention Deficit Hyperactivity Disorder
NCT00969618	Phase 3	Completed	Nov 1, 2009	Jan 1, 2012	Attention Deficit Hyperactivity Disorder
NCT00760747	Approved	Completed	Sep 1, 2008	Sep 1, 2010	Attention Deficit Hyperactivity Disorder
NCT00687609	Approved	Terminated	Sep 1, 2008	Jun 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00636818	Phase 2	Completed	Mar 1, 2008	Oct 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00530335	Phase 2	Completed	Sep 1, 2007	Apr 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00471354	Approved	Completed	Apr 1, 2007	Nov 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00918567	Approved	Completed	Jan 1, 2007	Sep 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00299234	Approved	Terminated	Jun 1, 2006	Dec 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00320528	Phase 3	Completed	Apr 1, 2006	Oct 1, 2008	Attention Deficit Disorder With Hyperactivity
NCT00252278	Approved	UNKNOWN	Nov 1, 2005	—	Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00255138	Phase 3	Withdrawn	Nov 1, 2005	—	Cancer
NCT00953862	Pre-clinical	Completed	Jul 1, 2005	Apr 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00191633	Approved	Completed	Apr 1, 2005	Jun 1, 2006	Attention-Deficit/Hyperactivity Disorder
NCT00286949	Pre-clinical	Completed	Jan 6, 2005	Jun 30, 2008	Parkinson's Disease
NCT00488163	Approved	Completed	Jan 1, 2005	Jun 1, 2007	Schizophrenia
NCT00191737	Phase 3	Completed	Oct 1, 2004	Feb 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191516	Phase 3	Completed	Oct 1, 2004	Feb 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191880	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191035	Approved	Completed	Mar 1, 2004	Nov 1, 2006	Attention-Deficit/Hyperactivity Disorder

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)

See all competitors

Product	Company	Stage	Hype Score
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
100mg SPN-812 + Placebo	Supernus Pharmaceuticals	Approved	44
SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812	Supernus Pharmaceuticals	Phase 2	29
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29